All lobbying filings

Manatt, Phelps, and Phillips

Manatt, Phelps, and Phillips filed a Q3 report for Denali Therapeutics on October 5, 2026, reporting $70,000 in lobbying income.

Lobbying for Denali Therapeutics · Biopharmaceutical Company

As filed: MANATT, PHELPS, AND PHILLIPS for DENALI THERAPEUTICS.

All filings by Manatt, Phelps, and Phillips · Everything Denali Therapeutics has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 5, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to the Rare Pediatric Disease Priority Review Voucher (PRV) Program; Rare disease drug development

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.